ArticleOncoTargets and therapy2018
Down-regulation of CXCL11 inhibits colorectal cancer cell growth and epithelial-mesenchymal transition.
Article in OncoTargets and therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 43 citations in OpenAlex.
- Tri-Combination Antiretroviral Therapy Induces Dose- and Time-Dependent Disruption of Intestinal Epithelial Barrier Function and Repair Responses in Human T84 Cells.Journal of xenobiotics · 2026Article
- CXCL11: A Novel Biomarker in Colorectal Cancer as Metastasis Predictor.OncoTargets and therapy · 2025Article
- Article
- Siglec-15 as a New Perspective Therapy Target in Human Giant Cell Tumor of Bone.Current oncology (Toronto, Ont.) · 2022Article
- Cancer Stem Cells in Tumor Microenvironment of Adenocarcinoma of the Stomach, Colon, and Rectum.Cancers · 2022Review
- Chemokines in progression, chemoresistance, diagnosis, and prognosis of colorectal cancer.Frontiers in immunology · 2022Review
- Pro-tumorigenic role of type 2 diabetes-induced cellular senescence in colorectal cancer.Frontiers in oncology · 2022Review
- Link of sorafenib resistance with the tumor microenvironment in hepatocellular carcinoma: Mechanistic insights.Frontiers in pharmacology · 2022Review
- Colorectal cancer extracellular acidosis decreases immune cell killing and is partially ameliorated by pH-modulating agents that modify tumor cell cytokine profiles.American journal of cancer research · 2022Article
- Contribution of CXCR3-mediated signaling in the metastatic cascade of solid malignancies.Biochimica et biophysica acta. Reviews on cancer · 2021Review
- Identification of key genes in cutaneous squamous cell carcinoma: a transcriptome sequencing and bioinformatics profiling study.Annals of translational medicine · 2021Article
- Development and verification of an immune-related gene pairs prognostic signature in ovarian cancer.Journal of cellular and molecular medicine · 2021Article
- miR-1298-5p Influences the Malignancy Phenotypes of Breast Cancer Cells by InhibitingCancer management and research · 2021Article
- CXCL11 Correlates With Antitumor Immunity and an Improved Prognosis in Colon Cancer.Frontiers in cell and developmental biology · 2021Article
- Elevated RBP-Jκ and CXCL11 Expression in Colon Cancer is Associated with an Unfavorable Clinical Outcome.Cancer management and research · 2021Article
- The Role of Chemokines in the Development of Gastric Cancer - Diagnostic and Therapeutic Implications.International journal of molecular sciences · 2020Review
- Transcriptome Profile of Next Generation Sequence Data Related to Inflammation on Nasopharyngeal Carcinoma Cases in Indonesia.Asian Pacific journal of cancer prevention : APJCP · 2020Article
- CXCL11-CXCR3 Axis Mediates Tumor Lymphatic Cross Talk and Inflammation-Induced Tumor, Promoting Pathways in Head and Neck Cancers.The American journal of pathology · 2020Article
- CXCL1 Regulated by miR-302e Is Involved in Cell Viability and Motility of Colorectal CancerFrontiers in oncology · 2020Article
- Construction of a CXC Chemokine-Based Prediction Model for the Prognosis of Colon Cancer.BioMed research international · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe poor prognosis of colorectal cancer (CRC) largely results from local invasion and tumor metastases. Epithelial-mesenchymal transition (EMT) is a key step in the progression of solid tumors and plays a vital role in tumor metastasis. Recent studies demonstrate that C-X-C motif chemokine 11 (CXCL11) is involved in various cancers' progression. However, its biological activity in CRC needs deeper exploration.
methodsThe level of CXCL11 in CRC tissues and cell lines was determined using the quantitative real-time PCR (qRT-PCR) assay. The MTT, colony formation, wound healing and Transwell invasion assays were applied to assess the role of CXCL11 in CRC cell growth, migration and invasion, in vitro, respectively. A xenograft model was constructed to analyze the function of CXCL11 in CRC cell growth in vivo.
resultsCXCL11 was over-expressed in CRC tissues and cell lines. Repression of CXCL11 significantly inhibited CRC cell migration, invasion and EMT in vitro. In addition, down-regulation of CXCL11 reduced CRC cell growth and metastasis in vivo. Finally, we revealed that repression of CXCL11 inhibited the metastatic ability of CRC cell in a N-cadherin dependent manner.
conclusionIn summary, this study explicates the oncogenic activities of CXCL11 in CRC cell growth and metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.